Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.60 |
| ▸ | PDE6D | O43924 | 1/20 | 0.53 |
| ▸ | PDE6A | P16499 | 1/20 | 0.53 |
| ▸ | PDE6G | P18545 | 1/20 | 0.53 |
| ▸ | PDE6B | P35913 | 1/20 | 0.53 |
| ▸ | PDE6C | P51160 | 1/20 | 0.53 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429137 | 0.91 | PDE5A (0.60) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL1285507 | 0.89 | MAPT (0.51) | PDE5AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL651326 | 0.87 | PDE5A (0.56) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL441445 | 0.86 | PDE5A (0.55) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL4428236 | 0.85 | PDE5A (0.56) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL29409637 | 0.85 | TP53 (0.62) | THRBMAPTMEN1KMT2AKDM4E | |
| SCHEMBL29409630 | 0.85 | TP53 (0.62) | THRBMAPTMEN1KMT2AKDM4E | |
| SCHEMBL6314401 | 0.85 | TP53 (0.62) | THRBMAPTMEN1KMT2AKDM4E | |
| SCHEMBL30900720 | 0.84 | NMT2 (0.60) | MAPTMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL538191 | 0.84 | NMT2 (0.60) | MAPTMEN1KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
| CN-1280568-A | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2001-01-17 | — | — | CN | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5650415-A | INHIBITORS OF CELL PROLIFERATION/DIFFERENTIATION, ANTITUMOR, ANTICANCER, TREATMENT OF FIBROTIC DISORDERS, BLOOD VESSEL PROLIFERATION | SUGEN, INC. (US) | 1997-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | PDE5A 1747/4885PDE6D 2760/4885PDE6A 3050/4885 |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | PDE5A 198/4885PDE6D 1808/4885PDE6A 489/4885 |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | PDE5A 4815/4885PDE6D 4848/4885PDE6A 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.